Met-flox Mouse
Common Name
Met-flox
제품 ID
S-CKO-03717
Backgroud
C57BL/6JCya
품종 계통계통 ID
CKOCMP-17295-Met-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Met-flox Mouse (카탈로그 번호 S-CKO-03717)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Met-flox
품종 계통계통 ID
CKOCMP-17295-Met-B6J-VA
유전자명
제품 ID
S-CKO-03717
유전자 별칭
HGF, HGFR, Par4, c-Met
배경
C57BL/6JCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 6
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000115443
NCBI 전사체 ID
NM_008591
타겟 영역
Exon 7
유효 영역 크기
~1.4 kb
유전자 연구 개요
Met, also known as the c-Met proto-oncogene, is a receptor tyrosine kinase. Its ligand is hepatocyte growth factor (HGF). The HGF/MET axis plays a key role in multiple biological processes such as cellular proliferation, migration, and invasion, which are crucial during embryonic development and tissue repair. Aberrant activation of this pathway due to mutations, fusions, amplification, or abnormal ligand production is associated with cancer development [1,2,3,4,5,6].
Developing MET-targeted therapies has been challenging. Historically, focusing on MET-expressing cancers had limited success as MET expression without a genomic marker of dependence poorly predicts treatment benefit [1]. However, high-level MET amplification, activating mutations (including kinase or extracellular domain mutations and exon 14 skipping), and fusions are now recognized as oncogenic drivers [1]. For instance, in non-small-cell lung cancer (NSCLC), MET exon 14 mutations are a distinct molecular subtype, often associated with advanced age, and stage-dependent MET genomic amplification and c-Met overexpression [7]. MET-targeted therapies' efficacy varies by MET alteration category, and higher levels of MET amplification increase the likelihood of benefit, though an optimal diagnostic cut-off for MET copy number gains is yet to be agreed upon [1]. In gliomas, the dysregulated MET signaling pathway is involved in tumor progression, and combined targeted therapy for this pathway could be a novel treatment strategy [5]. In renal cell carcinoma (RCC), the MET pathway is targeted by novel agents, and MET alterations can act as primary or secondary drivers of tumor growth [6].
In conclusion, Met is a crucial gene with its HGF/MET axis playing essential roles in normal biological processes and disease, especially cancer. Research on Met-targeted therapies has highlighted the significance of genomic alterations in predicting treatment response. Understanding Met's role through studies in various cancer types helps in developing more effective therapeutic strategies for cancer treatment.
References:
1. Guo, Robin, Luo, Jia, Chang, Jason, Arcila, Maria, Drilon, Alexander. 2020. MET-dependent solid tumours - molecular diagnosis and targeted therapy. In Nature reviews. Clinical oncology, 17, 569-587. doi:10.1038/s41571-020-0377-z. https://pubmed.ncbi.nlm.nih.gov/32514147/
2. Oliveres, Helena, Pineda, Estela, Maurel, Joan. 2019. MET inhibitors in cancer: pitfalls and challenges. In Expert opinion on investigational drugs, 29, 73-85. doi:10.1080/13543784.2020.1699532. https://pubmed.ncbi.nlm.nih.gov/31783719/
3. Kumaki, Yuichi, Oda, Goshi, Ikeda, Sadakatsu. 2023. Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches. In Cancers, 15, . doi:10.3390/cancers15184552. https://pubmed.ncbi.nlm.nih.gov/37760522/
4. Lombardi, Andrea Maria, Sangiolo, Dario, Vigna, Elisa. 2024. MET Oncogene Targeting for Cancer Immunotherapy. In International journal of molecular sciences, 25, . doi:10.3390/ijms25116109. https://pubmed.ncbi.nlm.nih.gov/38892318/
5. Cheng, Fangling, Guo, Dongsheng. 2019. MET in glioma: signaling pathways and targeted therapies. In Journal of experimental & clinical cancer research : CR, 38, 270. doi:10.1186/s13046-019-1269-x. https://pubmed.ncbi.nlm.nih.gov/31221203/
6. Nandagopal, Lakshminarayanan, Sonpavde, Guru P, Agarwal, Neeraj. 2019. Investigational MET inhibitors to treat Renal cell carcinoma. In Expert opinion on investigational drugs, 28, 851-860. doi:10.1080/13543784.2019.1673366. https://pubmed.ncbi.nlm.nih.gov/31554440/
7. Awad, Mark M, Oxnard, Geoffrey R, Jackman, David M, Hammerman, Peter S, Sholl, Lynette M. 2016. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. In Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34, 721-30. doi:10.1200/JCO.2015.63.4600. https://pubmed.ncbi.nlm.nih.gov/26729443/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
